ReviewBreathe (Sheffield, England)2021
Precision medicine in bronchiectasis.
Review in Breathe (Sheffield, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype.Life (Basel, Switzerland) · 2026Article
- Review
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Prevalence and types of treatable traits in bronchiectasis: a multicentre, cross-sectional study.ERJ open research · 2025Article
- Bronchiectasis and sinonasal diseases: a narrative review.ERJ open research · 2025Review
- Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.The European respiratory journal · 2025Review
- Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review.Journal of thoracic disease · 2025Review
- Neutrophilic inflammation in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Two novel genetic variants in the WFDC2 gene from patients with bronchiectasis.Respiratory research · 2025Article
- Targeting neutrophil serine proteases in bronchiectasis.The European respiratory journal · 2025Review
- Integrating hot topics and implementation of treatable traits in asthma.The European respiratory journal · 2024Review
- Secondary Immunodeficiency and Non-cystic Fibrosis Bronchiectasis.Tuberculosis and respiratory diseases · 2024Article
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2023Article
- ERS International Congress 2022: highlights from the Airway Diseases Assembly.ERJ open research · 2023Review
- Personalising airway clearance in chronic suppurative lung diseases: a scoping review.ERJ open research · 2023Article
- Targeted therapy in respiratory disease.Breathe (Sheffield, England) · 2021Article
- Implementation of the treatable traits approach in a regional clinic: Improving health outcomes in adults with bronchiectasis.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis, due to its highly heterogenous nature, requires an individualised approach to therapy. Patients experience symptoms and exacerbations driven by a combination of impaired mucociliary clearance, airway inflammation and airway infection. Treatment of bronchiectasis aims to enhance airway clearance and to address the underlying causes of inflammation and infection susceptibility. Bronchiectasis has multiple causes and so the pathophysiology leading to individual symptoms and exacerbations are different between individuals. Standardised investigations are recommended by international guidelines to identify the underlying causes of bronchiectasis. The process of identifying the underlying biology within an individual is called "endotyping" and is an emerging concept across chronic diseases. Endotypes that have a specific treatment are referred to as "treatable traits" and a treatable traits approach to managing patients with bronchiectasis in a holistic and evidence-based manner is the key to improved outcomes. Bronchiectasis is an area of intense research. Endotyping allows identification of subsets of patients to allow medicines to be tested differently in the future where trials, rather than trying to achieve a "one size fits all" solution, can test efficacy in subsets of patients where the treatment is most likely to be efficacious.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.